Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Capecitabine/docetaxel combination therapy deemed cost effective in advanced or metastatic breast cancer
December 22nd, 2005
Capecitabine/docetaxel combination therapy was deemed a cost-effective treatment in advanced or metastatic breast cancer (MBC) in France. In a recent article published in the journal Bulletin du Cancer, scientists in France detailed a study conducted "to estimate the cost-effectiveness ratio of adopting capecitabine/docetaxel combination therapy in place of docetaxel alone, in France, in patients with MBC, resistant to, or relapsing after anthracycline-containing therapy, The SO 14999 trial is a multicenter trial, randomized, including 511 patients equitably divided between the 2 groups. In addition to efficacy data, medical resource consumption related to...
Source: Women's Health Weekly (2005-12-22)
|
